Dallah Healthcare Valuation
Is 4004 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4004 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4004 (SAR162) is trading above our estimate of fair value (SAR99.06)
Significantly Below Fair Value: 4004 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4004?
Other financial metrics that can be useful for relative valuation.
| What is 4004's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ر.س15.82b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.1x |
| Enterprise Value/EBITDA | 29.2x |
| PEG Ratio | 2.8x |
Price to Earnings Ratio vs Peers
How does 4004's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 37.8x | ||
4007 Al Hammadi Holding | 29.4x | 12.0% | ر.س8.9b |
4009 Middle East Healthcare | 46.5x | 21.2% | ر.س8.4b |
4002 Mouwasat Medical Services | 40.8x | 14.3% | ر.س26.8b |
4005 National Medical Care | 34.6x | 14.0% | ر.س8.3b |
4004 Dallah Healthcare | 43.9x | 16.0% | ر.س15.8b |
Price-To-Earnings vs Peers: 4004 is expensive based on its Price-To-Earnings Ratio (43.9x) compared to the peer average (37.8x).
Price to Earnings Ratio vs Industry
How does 4004's PE Ratio compare vs other companies in the Asian Healthcare Industry?
Price-To-Earnings vs Industry: 4004 is expensive based on its Price-To-Earnings Ratio (43.9x) compared to the Asian Healthcare industry average (22.1x).
Price to Earnings Ratio vs Fair Ratio
What is 4004's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 43.9x |
| Fair PE Ratio | 37.2x |
Price-To-Earnings vs Fair Ratio: 4004 is expensive based on its Price-To-Earnings Ratio (43.9x) compared to the estimated Fair Price-To-Earnings Ratio (37.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ر.س162.00 | ر.س154.38 -4.7% | 13.2% | ر.س183.00 | ر.س106.00 | n/a | 10 |
| Apr ’25 | ر.س171.40 | ر.س150.09 -12.4% | 12.5% | ر.س174.00 | ر.س106.00 | n/a | 9 |
| Mar ’25 | ر.س187.60 | ر.س147.26 -21.5% | 16.0% | ر.س165.00 | ر.س85.80 | n/a | 9 |
| Feb ’25 | ر.س165.20 | ر.س142.37 -13.8% | 16.8% | ر.س165.00 | ر.س85.80 | n/a | 9 |
| Jan ’25 | ر.س170.40 | ر.س142.37 -16.5% | 16.8% | ر.س165.00 | ر.س85.80 | n/a | 9 |
| Dec ’24 | ر.س166.00 | ر.س136.70 -17.7% | 16.9% | ر.س165.00 | ر.س85.80 | n/a | 9 |
| Nov ’24 | ر.س145.80 | ر.س134.09 -8.0% | 19.6% | ر.س170.50 | ر.س74.30 | n/a | 9 |
| Oct ’24 | ر.س142.00 | ر.س133.48 -6.0% | 20.8% | ر.س170.50 | ر.س74.30 | n/a | 8 |
| Sep ’24 | ر.س140.00 | ر.س135.98 -2.9% | 20.1% | ر.س170.50 | ر.س74.30 | n/a | 8 |
| Aug ’24 | ر.س173.80 | ر.س132.46 -23.8% | 23.7% | ر.س170.50 | ر.س76.20 | n/a | 8 |
| Jul ’24 | n/a | ر.س134.21 0% | 25.0% | ر.س181.00 | ر.س76.20 | n/a | 8 |
| Jun ’24 | ر.س163.40 | ر.س128.09 -21.6% | 25.8% | ر.س181.00 | ر.س76.20 | n/a | 8 |
| May ’24 | ر.س170.00 | ر.س119.98 -29.4% | 26.4% | ر.س176.00 | ر.س66.80 | ر.س162.00 | 7 |
| Apr ’24 | ر.س154.00 | ر.س118.55 -23.0% | 26.3% | ر.س176.00 | ر.س66.80 | ر.س171.40 | 7 |
| Mar ’24 | ر.س143.40 | ر.س120.37 -16.1% | 25.3% | ر.س186.00 | ر.س72.90 | ر.س187.60 | 8 |
| Feb ’24 | ر.س136.00 | ر.س120.37 -11.5% | 25.3% | ر.س186.00 | ر.س72.90 | ر.س165.20 | 8 |
| Jan ’24 | ر.س146.40 | ر.س119.61 -18.3% | 25.7% | ر.س186.00 | ر.س72.90 | ر.س170.40 | 8 |
| Dec ’23 | ر.س171.80 | ر.س120.15 -30.1% | 23.7% | ر.س186.00 | ر.س86.20 | ر.س166.00 | 8 |
| Nov ’23 | ر.س161.80 | ر.س118.39 -26.8% | 27.9% | ر.س197.00 | ر.س85.10 | ر.س145.80 | 8 |
| Oct ’23 | ر.س158.00 | ر.س109.16 -30.9% | 16.0% | ر.س135.00 | ر.س83.30 | ر.س142.00 | 8 |
| Sep ’23 | ر.س119.80 | ر.س109.96 -8.2% | 14.8% | ر.س135.00 | ر.س89.70 | ر.س140.00 | 8 |
| Aug ’23 | ر.س123.60 | ر.س105.47 -14.7% | 16.0% | ر.س135.00 | ر.س78.50 | ر.س173.80 | 9 |
| Jul ’23 | ر.س110.80 | ر.س102.78 -7.2% | 17.2% | ر.س135.00 | ر.س78.50 | n/a | 8 |
| Jun ’23 | ر.س116.20 | ر.س94.02 -19.1% | 15.2% | ر.س126.00 | ر.س78.50 | ر.س163.40 | 9 |
| May ’23 | ر.س120.40 | ر.س90.04 -25.2% | 17.1% | ر.س124.00 | ر.س74.90 | ر.س170.00 | 9 |
Analyst Forecast: Target price is lower than the current share price.